Alzheimers Disease Recruiting Phase 2 / 3 Trials for Solanezumab (DB11756)

IndicationStatusPhase
DBCOND0036596 (Alzheimers Disease)Recruiting2 / 3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01760005Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation.Treatment